
Petra Langerbeins/touchoncology.com
Feb 1, 2025, 13:44
CLL12 study supports using the watch-and-wait approach for early-stage CLL
Jonathan Friedberg, Director of Wilmot Cancer Institute, shared a recent article by Petra Langerbeins, et al. on X:
CLL12 study supports using the watch-and-wait approach as the standard of care for early-stage CLL, including high-risk patients.
Ongoing SWOG Cancer Research Network S1925 trial evaluates early venetoclax-based treatment for high risk patients.
Authors: Petra Langerbeins, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 2, 2025, 11:58
Mar 2, 2025, 11:54
Mar 2, 2025, 11:50
Mar 2, 2025, 10:50
Mar 2, 2025, 10:22